Journament

Keyword Connections - docetaxel Keywords

Connection Type	Connection
Journals	Chemical communications (Cambridge, England) journal of cellular biochemistry carcinogenesis drug delivery european journal of pharmaceutics and biopharmaceutics : official journal of arbeitsgemeinschaft fur pharmazeutische verfahrenstechnik ev translational lung cancer research
Research Groups	No Research Group Connected
Bibliographies	[1] Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review. [2] Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer. [3] A carbon-based polymer dot sensor for breast cancer detection using peripheral blood immunocytes. [4] GLIS1, a novel hypoxia-inducible transcription factor, promotes breast cancer cell motility via activation of WNT5A. [5] Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. [6] docetaxel-loaded lipid microbubbles combined with ultrasound-triggered microbubble destruction for targeted tumor therapy in mhcc-h cells [7] clinical study of docetaxel, prednisone and bevacizunab in the treatment of hormone refractory prostate cancer [8] advance of second-line chemotherapy in advanced non-small cell lung cancer [9] feasibility of classical secondary hormonal therapies prior to docetaxel therapy in japanese patients with castration-resistant prostate cancer: multicenter retrospective study [10] icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study [11] resistance to taxanes in triple-negative breast cancer associates with the dynamics of a cd49f+ tumor-initiating population [12] Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study. [13] Immune-triggered cancer treatment by intestinal lymphatic delivery of docetaxel-loaded nanoparticle. [14] Development of synthetic high-density lipoprotein-based ApoA-I mimetic peptide-loaded docetaxel as a drug delivery nanocarrier for breast cancer chemotherapy. [15] Antitumor Efficacy of Docetaxel-loaded Nanocarrier against Esophageal Cancer Cell Bearing Mice Model [16] Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. [17] Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends. [18] Dnajb8, a member of the heat shock protein 40 family has a role in the tumor initiation and resistance to docetaxel but is dispensable for stress response [19] Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. [20] Selective Targeting of the Hedgehog Signaling Pathway by PBM Nanoparticles in Docetaxel-Resistant Prostate Cancer [21] Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials [22] docetaxel-loaded lipid microbubbles combined with ultrasound-triggered microbubble destruction for targeted tumor therapy in mhcc-h cells [23] aqueous extract of solanum nigrum leaf activates autophagic cell death and enhances docetaxel-induced cytotoxicity in human endometrial carcinoma cells [24] clinical study of docetaxel, prednisone and bevacizunab in the treatment of hormone refractory prostate cancer [25] pharmacokinetics and in vitro/in vivo antitumor efficacy of aptamer-targeted ecoflex® nanoparticles for docetaxel delivery in ovarian cancer [26] efficacy of abiraterone and enzalutamide in pre- and postdocetaxel castration-resistant prostate cancer: a trial-level meta-analysis [27] feasibility of classical secondary hormonal therapies prior to docetaxel therapy in japanese patients with castration-resistant prostate cancer: multicenter retrospective study [28] presentation and management of docetaxel-related adverse effects in patients with breast cancer [29] the chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells [30] lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor i receptor levels [31] avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células an economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer [32] icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study [33] bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel [34] docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model [35] Chemotherapy-Induced Peripheral Neurotoxicity as A Risk Factor for Poor Sleep Quality in Breast Cancer Survivors Treated with Docetaxel. [36] Multifunctional Nanoparticles Loading with Docetaxel and GDC0941 for Reversing Multidrug Resistance Mediated by PI3K/Akt Signal Pathway [37] Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study.